✦ LIBER ✦

Long-Term Management of Prolactinomas—Use of Long-Acting Dopamine Agonists

✍ Scribed by David M. Cook

Book ID: 106515821
Publisher: Springer
Year: 2005
Tongue: English
Weight: 134 KB
Volume: 6
Category: Article
ISSN: 1389-9155
DOI: 10.1007/s11154-005-5220-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recommendations for use of long-acting β

Recommendations for use of long-acting β2-agonists

📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 252 KB

Long-term tolerability and efficacy of c

Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease

✍ R. Inzelberg; P. Nisipeanu; M. J. Rabey; Prof. A. D. Korczyn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

## Abstract Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a

Giant prolactinomas: clinical management

Giant prolactinomas: clinical management and long-term follow up

✍ Shrivastava, Raj K.; Arginteanu, Marc S.; King, Wesley A.; Post, Kalmon D. 📂 Article 📅 2002 🏛 American Association of Neurological Surgeons 🌐 English ⚖ 262 KB

Long term follow-up of patients with pro

Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience

✍ Panagiotis Anagnostis; Fotini Adamidou; Stergios A. Polyzos; Zoe Efstathiadou; E 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 233 KB

Temozolomide in the management of dopami

Temozolomide in the management of dopamine agonist–resistant prolactinomas

✍ B. C. Whitelaw; D. Dworakowska; N. W. Thomas; S. Barazi; P. Riordan-Eva; A. P. K 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB

Benefits of long-acting β2-agonists

✍ Lipworth, Brian J. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 49 KB